Cargando…

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

BACKGROUND: The impact of viral subtype on the rate of sustained virological response (SVR) to antiviral therapy in patients chronically infected with hepatitis C genotype 1 subtype 1a and 1b has not been extensively investigated. The aim of this study is to determine whether the HCV genotype 1 subt...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellicelli, Adriano M, Romano, Mario, Stroffolini, Tommaso, Mazzoni, Ettore, Mecenate, Fabrizio, Monarca, Roberto, Picardi, Antonio, Bonaventura, Maria Elena, Mastropietro, Cristina, Vignally, Pascal, Andreoli, Arnaldo, Marignani, Massimo, D’Ambrosio, Cecilia, Miglioresi, Lucia, Nosotti, Lorenzo, Mitidieri, Olga, Gentilucci, Umberto Vespasiani, Puoti, Claudio, Barbaro, Giuseppe, Barlattani, Angelo, Furlan, Caterina, Barbarini, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526494/
https://www.ncbi.nlm.nih.gov/pubmed/23157720
http://dx.doi.org/10.1186/1471-230X-12-162
_version_ 1782253573686427648
author Pellicelli, Adriano M
Romano, Mario
Stroffolini, Tommaso
Mazzoni, Ettore
Mecenate, Fabrizio
Monarca, Roberto
Picardi, Antonio
Bonaventura, Maria Elena
Mastropietro, Cristina
Vignally, Pascal
Andreoli, Arnaldo
Marignani, Massimo
D’Ambrosio, Cecilia
Miglioresi, Lucia
Nosotti, Lorenzo
Mitidieri, Olga
Gentilucci, Umberto Vespasiani
Puoti, Claudio
Barbaro, Giuseppe
Barlattani, Angelo
Furlan, Caterina
Barbarini, Giorgio
author_facet Pellicelli, Adriano M
Romano, Mario
Stroffolini, Tommaso
Mazzoni, Ettore
Mecenate, Fabrizio
Monarca, Roberto
Picardi, Antonio
Bonaventura, Maria Elena
Mastropietro, Cristina
Vignally, Pascal
Andreoli, Arnaldo
Marignani, Massimo
D’Ambrosio, Cecilia
Miglioresi, Lucia
Nosotti, Lorenzo
Mitidieri, Olga
Gentilucci, Umberto Vespasiani
Puoti, Claudio
Barbaro, Giuseppe
Barlattani, Angelo
Furlan, Caterina
Barbarini, Giorgio
author_sort Pellicelli, Adriano M
collection PubMed
description BACKGROUND: The impact of viral subtype on the rate of sustained virological response (SVR) to antiviral therapy in patients chronically infected with hepatitis C genotype 1 subtype 1a and 1b has not been extensively investigated. The aim of this study is to determine whether the HCV genotype 1 subtypes 1a and 1b respond differently to treatment with PEGylated interferon (PEG-IFN) plus ribavirin. METHODS: For 48 weeks, 388 “naïve”genotype 1 patients were treated weekly with PEG-IFN α-2a or PEG-INF α-2b combined with daily ribavirin (1000–1200 mg/day). The numbers of patients in whom HCV-RNA was undetectable were compared after 4 (rapid virological response, RVR), 12 (early virological response, EVR), and 48 (end treatment virological response, ETR) weeks of treatment as well as 24 weeks after the last treatment (sustained virological response, SVR). RESULTS: The rate of SVR was higher in subtype 1a patients than subtype 1b patients (55% vs. 43%; p < 0.02). Multiple logistic regression analysis showed that infection with genotype 1a (odds ratio(OR) : 1.8; 95% confidence interval (CI): 1.4 to 4.1), age < 50 years (OR:7.0; 95% CI 1.1 to 21.2), alanine aminotransferase level (ALT)<100 IU/ml (OR:2.1; 95% CI: 1.3 to3.5), HCV-RNA < 5.6 log(10) IU/ml (OR: 3.2; 95% CI: 2.7 to 6.9) and fibrosis score < S3 (OR: 3.8; 95% CI:3.2 to 7.4), were all independent predictors of SVR. CONCLUSION: Dual antiviral therapy is more effective against HCV subtype 1a than against subtype 1b and this difference is independent of other factors that may favour viral clearance. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01342003
format Online
Article
Text
id pubmed-3526494
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35264942012-12-20 HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b Pellicelli, Adriano M Romano, Mario Stroffolini, Tommaso Mazzoni, Ettore Mecenate, Fabrizio Monarca, Roberto Picardi, Antonio Bonaventura, Maria Elena Mastropietro, Cristina Vignally, Pascal Andreoli, Arnaldo Marignani, Massimo D’Ambrosio, Cecilia Miglioresi, Lucia Nosotti, Lorenzo Mitidieri, Olga Gentilucci, Umberto Vespasiani Puoti, Claudio Barbaro, Giuseppe Barlattani, Angelo Furlan, Caterina Barbarini, Giorgio BMC Gastroenterol Research Article BACKGROUND: The impact of viral subtype on the rate of sustained virological response (SVR) to antiviral therapy in patients chronically infected with hepatitis C genotype 1 subtype 1a and 1b has not been extensively investigated. The aim of this study is to determine whether the HCV genotype 1 subtypes 1a and 1b respond differently to treatment with PEGylated interferon (PEG-IFN) plus ribavirin. METHODS: For 48 weeks, 388 “naïve”genotype 1 patients were treated weekly with PEG-IFN α-2a or PEG-INF α-2b combined with daily ribavirin (1000–1200 mg/day). The numbers of patients in whom HCV-RNA was undetectable were compared after 4 (rapid virological response, RVR), 12 (early virological response, EVR), and 48 (end treatment virological response, ETR) weeks of treatment as well as 24 weeks after the last treatment (sustained virological response, SVR). RESULTS: The rate of SVR was higher in subtype 1a patients than subtype 1b patients (55% vs. 43%; p < 0.02). Multiple logistic regression analysis showed that infection with genotype 1a (odds ratio(OR) : 1.8; 95% confidence interval (CI): 1.4 to 4.1), age < 50 years (OR:7.0; 95% CI 1.1 to 21.2), alanine aminotransferase level (ALT)<100 IU/ml (OR:2.1; 95% CI: 1.3 to3.5), HCV-RNA < 5.6 log(10) IU/ml (OR: 3.2; 95% CI: 2.7 to 6.9) and fibrosis score < S3 (OR: 3.8; 95% CI:3.2 to 7.4), were all independent predictors of SVR. CONCLUSION: Dual antiviral therapy is more effective against HCV subtype 1a than against subtype 1b and this difference is independent of other factors that may favour viral clearance. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01342003 BioMed Central 2012-11-16 /pmc/articles/PMC3526494/ /pubmed/23157720 http://dx.doi.org/10.1186/1471-230X-12-162 Text en Copyright ©2012 Pellicelli et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Pellicelli, Adriano M
Romano, Mario
Stroffolini, Tommaso
Mazzoni, Ettore
Mecenate, Fabrizio
Monarca, Roberto
Picardi, Antonio
Bonaventura, Maria Elena
Mastropietro, Cristina
Vignally, Pascal
Andreoli, Arnaldo
Marignani, Massimo
D’Ambrosio, Cecilia
Miglioresi, Lucia
Nosotti, Lorenzo
Mitidieri, Olga
Gentilucci, Umberto Vespasiani
Puoti, Claudio
Barbaro, Giuseppe
Barlattani, Angelo
Furlan, Caterina
Barbarini, Giorgio
HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
title HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
title_full HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
title_fullStr HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
title_full_unstemmed HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
title_short HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
title_sort hcv genotype 1a shows a better virological response to antiviral therapy than hcv genotype 1b
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526494/
https://www.ncbi.nlm.nih.gov/pubmed/23157720
http://dx.doi.org/10.1186/1471-230X-12-162
work_keys_str_mv AT pellicelliadrianom hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT romanomario hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT stroffolinitommaso hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT mazzoniettore hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT mecenatefabrizio hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT monarcaroberto hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT picardiantonio hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT bonaventuramariaelena hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT mastropietrocristina hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT vignallypascal hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT andreoliarnaldo hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT marignanimassimo hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT dambrosiocecilia hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT miglioresilucia hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT nosottilorenzo hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT mitidieriolga hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT gentilucciumbertovespasiani hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT puoticlaudio hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT barbarogiuseppe hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT barlattaniangelo hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT furlancaterina hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b
AT barbarinigiorgio hcvgenotype1ashowsabettervirologicalresponsetoantiviraltherapythanhcvgenotype1b